Ocugen (OCGN) Interest & Investment Income (2016 - 2026)
Ocugen posted quarterly Interest & Investment Income of $100000.0 for Q1 2026, down 66.67% year-on-year from $300000.0 in Q1 2025, and down 18.03% on a QoQ basis from $122000.0 in Q4 2025.
Ocugen (OCGN) has 9 years of Interest & Investment Income data on file, last reported at $100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 66.67% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at -$629000.0 (down 152.81% YoY), and the FY2025 full-year result was $922000.0, down 26.3% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $100000.0, down from $122000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $408000.0 in Q4 2024 and bottomed at -$1.1 million in Q2 2025.
- The 3-year median for Interest & Investment Income is $207000.0 (2025), against an average of $96000.0.
- Peak annual rise in Interest & Investment Income reached 0.66% in 2025, while the deepest fall reached 711.56% in 2025.
- A 3-year view of Interest & Investment Income shows it stood at $408000.0 in 2024, then slumped by 70.1% to $122000.0 in 2025, then retreated by 18.03% to $100000.0 in 2026.
- The last three Interest & Investment Income figures came in at $100000.0 (Q1 2026), $122000.0 (Q4 2025), and $207000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 122,000.00 |
| Sep 30, 2025 | 207,000.00 |
| Jun 30, 2025 | -1.06 Mn |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 408,000.00 |
| Sep 30, 2024 | 310,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Mar 31, 2024 | 302,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Dec 31, 2020 | 1,065.00 |
| Mar 31, 2020 | 119.00 |
| Dec 31, 2019 | 107.00 |
| Sep 30, 2019 | 136.00 |
| Jun 30, 2019 | 377.00 |
| Mar 31, 2019 | 594.00 |
| Dec 31, 2018 | 1,820.00 |
| Sep 30, 2018 | 3,762.00 |
| Jun 30, 2018 | 32,000.00 |
| Mar 31, 2018 | 37,000.00 |
| Dec 31, 2017 | 20,000.00 |
| Sep 30, 2017 | 39,000.00 |
| Jun 30, 2017 | 40,000.00 |
| Mar 31, 2017 | 35,000.00 |
| Dec 31, 2016 | -5,000.00 |
| Sep 30, 2016 | -20,000.00 |
| Jun 30, 2016 | -17,000.00 |
| Mar 31, 2016 | -19,000.00 |